Actively Recruiting
Evaluation of HMPL-A580 Safety, Tolerability, and Dose Optimization in Adults With Advanced or Metastatic Solid Tumors
Led by Hutchmed · Updated on 2026-09-18
186
Participants Needed
14
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating HMPL-A580 in adults with unresectable, advanced, or metastatic solid tumors. This first-in-human, multicenter, open-label, phase IIIa study aims to assess the safety, tolerability, and optimal dosing of HMPL-A580. The study also seeks to understand the preliminary efficacy of the treatment to determine recommended doses for future phase II or III studies. Participants receive HMPL-A580 in two parts Part A involves dose escalation with six predefined dose levels to find the maximum tolerated dose or recommended dose for expansion. Part B focuses on dose expansion and optimization to further evaluate safety and anti-tumor activity in selected solid tumors. These treatments are given under medical supervision as part of the study. During the study, participants are closely monitored through assessments of treatment-emergent adverse events, objective tumor response, disease control, and progression-free survival. Evaluations occur over approximately 12 to 24 months, including safety and efficacy measures. Participants remain under observation for up to two years to collect these outcomes and ensure ongoing safety and tolerability of HMPL-A580.
CONDITIONS
Brief Title
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here